CN101621990A - 可口服施用的膜剂 - Google Patents
可口服施用的膜剂 Download PDFInfo
- Publication number
- CN101621990A CN101621990A CN200880006235A CN200880006235A CN101621990A CN 101621990 A CN101621990 A CN 101621990A CN 200880006235 A CN200880006235 A CN 200880006235A CN 200880006235 A CN200880006235 A CN 200880006235A CN 101621990 A CN101621990 A CN 101621990A
- Authority
- CN
- China
- Prior art keywords
- disintegrable films
- oral disintegrable
- described oral
- nicotine
- films
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013543 active substance Substances 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims description 34
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 30
- -1 elsinan Polymers 0.000 claims description 21
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 17
- 229920000642 polymer Polymers 0.000 claims description 17
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 14
- 235000017550 sodium carbonate Nutrition 0.000 claims description 14
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 13
- 229960002715 nicotine Drugs 0.000 claims description 13
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 13
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 13
- 229920001285 xanthan gum Polymers 0.000 claims description 13
- 235000010493 xanthan gum Nutrition 0.000 claims description 13
- 239000000230 xanthan gum Substances 0.000 claims description 13
- 229940082509 xanthan gum Drugs 0.000 claims description 13
- 235000010443 alginic acid Nutrition 0.000 claims description 12
- 239000000783 alginic acid Substances 0.000 claims description 12
- 229920000615 alginic acid Polymers 0.000 claims description 12
- 229960001126 alginic acid Drugs 0.000 claims description 12
- 150000004781 alginic acids Chemical class 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 11
- LDMPZNTVIGIREC-ZGPNLCEMSA-N nicotine bitartrate Chemical group O.O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 LDMPZNTVIGIREC-ZGPNLCEMSA-N 0.000 claims description 11
- 229920001685 Amylomaize Polymers 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
- 229920001222 biopolymer Polymers 0.000 claims description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 9
- 238000004132 cross linking Methods 0.000 claims description 9
- 239000003292 glue Substances 0.000 claims description 9
- 239000000416 hydrocolloid Substances 0.000 claims description 9
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 9
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 9
- 229920002261 Corn starch Polymers 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000008120 corn starch Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 235000010418 carrageenan Nutrition 0.000 claims description 6
- 229920001525 carrageenan Polymers 0.000 claims description 6
- 229920003086 cellulose ether Polymers 0.000 claims description 6
- 150000002170 ethers Chemical class 0.000 claims description 6
- 210000002200 mouth mucosa Anatomy 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 229920000945 Amylopectin Polymers 0.000 claims description 5
- 229920002164 Polyalkylene glycol copolymer Polymers 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 229920002401 polyacrylamide Polymers 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 229920000856 Amylose Polymers 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 108010068370 Glutens Proteins 0.000 claims description 4
- 102000004407 Lactalbumin Human genes 0.000 claims description 4
- 108090000942 Lactalbumin Proteins 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 239000004368 Modified starch Substances 0.000 claims description 4
- 229920002494 Zein Polymers 0.000 claims description 4
- 108010055615 Zein Proteins 0.000 claims description 4
- 229920006243 acrylic copolymer Polymers 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 4
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 4
- 235000019426 modified starch Nutrition 0.000 claims description 4
- 229920001206 natural gum Polymers 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 229940071440 soy protein isolate Drugs 0.000 claims description 4
- 239000005019 zein Substances 0.000 claims description 4
- 229940093612 zein Drugs 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 3
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims description 3
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 3
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 235000011181 potassium carbonates Nutrition 0.000 claims description 3
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 3
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 230000003232 mucoadhesive effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 39
- 210000004379 membrane Anatomy 0.000 description 23
- 239000012528 membrane Substances 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 210000000214 mouth Anatomy 0.000 description 11
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 8
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 8
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 8
- 239000000619 acesulfame-K Substances 0.000 description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 8
- 229940041616 menthol Drugs 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000010489 acacia gum Nutrition 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 235000011182 sodium carbonates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- General Preparation And Processing Of Foods (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及口服可崩解膜剂,其具有粘膜粘附性,在使用者的口中于1至10分钟内完全崩解,包含碱性物质,并任选包含药学活性物质。
Description
本发明涉及可食用的并且任选包含药学活性物质的口服可崩解膜剂。本发明尤其涉及包含碱性物质的口服可崩解膜剂。本发明更尤其涉及包含碱性物质、在使用者口中于1至10分钟内、优选于2至6分钟内完全崩解、粘附于口腔粘膜的口服可崩解膜剂。
因此,本发明的一个优选实施方案涉及在口中不立即溶解(例如在1-10秒内不溶解)、而是需要较长崩解时间(例如1至10分钟)并且在该段时间内能很好地粘附于口腔粘膜的口服可崩解膜剂。开发这类更缓慢崩解的口服膜剂有多种原因,例如使药学活性物质被口腔粘膜有效吸收,或者例如获得碱性物质对唾液的更持久的中和作用。
具有粘膜粘附性的缓慢崩解的口服膜剂在本领域中是已知的。然而,发现当向所述缓慢崩解的口服膜剂的组合物中加入碱性物质时,所述膜剂的粘膜粘附性大幅度变差。组合物需要包含碱性物质的原因可能有多种,尤其可能是用于在施用口服可崩解膜剂后增加口腔中的pH。这可能是必须的例如以便将盐形式的药学活性物质转化成其未电离的形式(例如将烟碱酒石酸氢盐转化成烟碱)并从而促进所述药学活性物质的口腔吸收。
因此,本发明的一个目的是提供包含碱性物质、但是具有粘膜粘附性的缓慢崩解的口服膜剂。已经令人惊讶地发现,当向组合物中加入某些聚合物时,尽管有碱性物质存在,但膜剂仍保持粘膜粘附性。
因此,本发明涉及一种口服可崩解膜剂,其包含一个层,该层包含:
(a)成膜剂(film-forming agent),
(b)选自由交联羧甲基纤维素钠、玉米淀粉或其混合物组成的组的聚合物;和
(c)碱性物质。
在不包含任何其它药学活性物质的情况下,所述口服可崩解膜剂可通过粘附于口腔粘膜上并且例如历经数分钟中和唾液而是有用的,例如在食用酸性食物如水果(例如苹果)后或在食用含糖(其被口中的细菌分解成酸类)食物后。由于所述酸类可导致牙侵蚀,所以用包含碱性物质的口服可崩解膜剂中和所吸收的或所形成的酸类是有益的。
本发明的口服可崩解膜剂优选还包含至少一种药学活性物质(d)。
药学活性物质(d)可以是任何可口服施用的药学活性物质,其可用于例如在胃肠道中吸收或通过口腔粘膜吸收。优选的是通过口腔粘膜被吸收的药学活性物质,例如丁丙诺啡、硝酸甘油或烟碱。从对烟碱的提及可以看出,术语“药学活性物质”应作广义理解,其也包括用于口服施用的生理学活性物质。
在本发明的一个特定的实施方案中,药学活性物质(d)易于与碱性物质(c)发生化学反应,因此在所述口服可崩解膜剂中其与后者是分开的,以避免口服施用前任何过早的化学反应。(d)与(c)“分开”意指在施用前阻止这两种组分在口服可崩解膜剂内彼此发生化学反应,其可通过多种不同的方法来实现,例如通过在两层膜中的物理分离来实现。
药学活性物质(d)优选是烟碱活性剂。烟碱活性剂是例如游离烟碱、烟碱盐、烟碱复合物或其混合物。优选的是烟碱盐,特别是烟碱酒石酸氢盐。
成膜剂(a)是例如纤维素、纤维素醚衍生物、聚环氧烷、聚亚烷基二醇、聚亚烷基二醇共聚物、丙烯酸聚合物、丙烯酸共聚物、甲基丙烯酸聚合物、甲基丙烯酸共聚物、聚丙烯酰胺、支链淀粉、聚乙烯吡咯烷酮、聚乙烯醇、聚乙烯醇共聚物、羧乙烯聚合物(carboxyvinyl polymers)、改性淀粉、直链淀粉、高直链淀粉(high amylose starch)、羟丙基化高直链淀粉(hydroxypropylated high amylose starch)、糊精、果胶、壳多糖、脱乙酰壳多糖、果聚糖、爱生兰、胶原、明胶、玉米醇蛋白、谷蛋白、大豆蛋白分离物、乳清蛋白分离物、酪蛋白、合成的或天然存在的树胶、角叉菜胶(carrageanan)、海藻酸、海藻酸的盐、或其混合物。
优选的成膜剂(a)是纤维素、羟丙基甲基纤维素、羟乙基纤维素、羟丙基纤维素、聚环氧乙烷、聚环氧丙烷、聚乙二醇、聚丙二醇、丙烯酸聚合物、丙烯酸共聚物、甲基丙烯酸聚合物、甲基丙烯酸共聚物、聚丙烯酰胺、支链淀粉、聚乙烯吡咯烷酮、聚乙烯醇、羧乙烯聚合物、改性淀粉、直链淀粉、高直链淀粉、羟丙基化高直链淀粉、糊精、果胶、壳多糖、脱乙酰壳多糖、果聚糖、爱生兰、胶原、明胶、玉米醇蛋白、谷蛋白、大豆蛋白分离物、乳清蛋白分离物、酪蛋白、黄原胶、西黄蓍胶、瓜尔胶、金合欢胶(acacia gum)、阿拉伯胶(arabic gum)、角叉菜胶、海藻酸、海藻酸的盐、和其混合物。
优选的成膜剂(a)特别是纤维素、羟丙基甲基纤维素、羟乙基纤维素、羟丙基纤维素、聚环氧乙烷、聚乙二醇、聚丙烯酰胺、支链淀粉、聚乙烯吡咯烷酮、聚乙烯醇、改性淀粉、直链淀粉、高直链淀粉、羟丙基化高直链淀粉、糊精、果胶、壳多糖、胶原、明胶、玉米醇蛋白、谷蛋白、大豆蛋白分离物、乳清蛋白分离物、酪蛋白、黄原胶、西黄蓍胶、瓜尔胶、金合欢胶、阿拉伯胶、角叉菜胶、海藻酸、海藻酸的盐、和其混合物。
纤维素醚衍生物是例如羟丙基甲基纤维素、羟乙基纤维素、羟丙基纤维素、羟乙基甲基纤维素或甲基纤维素。
成膜剂(a)优选是水溶性的。
优选的聚合物(b)是交联羧甲基纤维素钠。玉米淀粉与玉蜀黍淀粉是同义词。
碱性物质(c)是例如碳酸钠、碳酸钾、碳酸氢钠、碳酸氢钾、氢氧化钠、氢氧化钾、或其任何混合物。
优选的碱性物质(c)是碳酸钠、碳酸钾、氢氧化钠、氢氧化钾、或其任何混合物。
本发明的一个特定的实施方案特征在于包含以下物质作为成膜剂(a)的那些口服可崩解膜剂:
(a1)水溶性成膜聚合物和
(a2)0.1-20%重量的水胶体/生物聚合物胶。
在后者中,优选那些包含0.1至15%、更优选0.3至5%、特别是0.5至3%重量的水胶体/生物聚合物胶(a2)的那些口服可崩解膜剂。
水溶性成膜聚合物(a1)是例如纤维素、纤维素醚衍生物、聚环氧烷、聚亚烷基二醇、聚亚烷基二醇共聚物、丙烯酸聚合物、丙烯酸共聚物、甲基丙烯酸聚合物、甲基丙烯酸共聚物、聚丙烯酰胺、支链淀粉、聚乙烯吡咯烷酮、聚乙烯醇、聚乙烯醇共聚物、羧乙烯聚合物、或其混合物。
优选的水溶性成膜聚合物(a1)是纤维素、纤维素醚衍生物、聚亚烷基二醇共聚物、聚乙烯醇、聚乙烯醇共聚物、或其混合物。
更优选的水溶性成膜聚合物(a1)是羟丙基甲基纤维素、羟乙基纤维素、羟丙基纤维素、聚乙烯醇、或其混合物。水溶性成膜聚合物(a1)特别是羟丙基甲基纤维素。
水胶体/生物聚合物胶(a2)是例如合成的或天然存在的树胶、角叉菜胶、海藻酸、海藻酸的盐、或其混合物。
水胶体/生物聚合物胶(a2)优选是黄原胶、西黄蓍胶、瓜尔胶、金合欢胶、阿拉伯胶、或其混合物。水胶体/生物聚合物胶(a2)特别是黄原胶。
可存在于本发明的口服可崩解膜剂中的其它组分有例如增塑剂。作为增塑剂,可以考虑例如多元醇,例如甘油、聚乙二醇、乙二醇或丙二醇;脂肪酸例如正-辛酸或油酸与甘油的单酯;山梨醇、聚山梨酯80[=聚氧乙烯(20)脱水山梨醇单油酸酯]、柠檬酸三乙酯、乙酰基柠檬酸三乙酯、柠檬酸三丁酯或邻苯二甲酸二乙酯。
优选的增塑剂是甘油、聚乙二醇、乙二醇、丙二醇、柠檬酸三乙酯、或其任何混合物;特别是甘油。
典型地,增塑剂的存在量为最终可食用膜剂(干重)的0.1至15%、优选1至8%、甚至更优选1.5至7%重量。在本发明的一个特定的实施方案中,增塑剂(B)是甘油并且其存在量为膜剂(干重)的1至12%、优选1至7%、更优选1.5至6%重量。
此外,本发明的可食用膜剂任选包含本领域中已知的常见辅料,例如矫味剂、甜味剂、抗氧化剂、稳定剂、着色剂、增溶剂或防腐剂。
一般而言,优选那些粘附于口腔粘膜的口服可崩解膜剂。
一般而言,优选那些可在使用者口中于1至10分钟、优选2至6分钟、特别是3至4分钟内完全崩解的口服可崩解膜剂。
“完全崩解”意指在患者口中没有肉眼可见的残留物。从实用的角度看,本发明的口服可崩解膜剂在所示的时间段内在口中完全溶解,附带一个从严格的科学角度制定的条件,即,膜剂的不溶于唾液的组分显然不溶解,而是被分散并且保持固体状态。
本发明的口服可崩解膜剂可具有一个或多个层并且典型地具有5-3000、优选10-1000、更优选20-500、特别是30-300微米的厚度。在另一个实施方案中,它们具有5至250微米的厚度。
本发明的口服可崩解膜剂不局限于任何特定的大小,它们优选是长方形、正方形或圆形,特别是长方形或正方形,典型地,其面积是2-20、优选2-12、更优选3-12、尤其是4-7平方厘米,如果是长方形或正方形,则典型地具有分别为0.5-3cm和2-20cm、优选1-3cm和2-5cm的边长。特别优选的尺寸是2.2cm×2.2cm(正方形)。
本发明的口服可崩解膜剂的有益特性例如可通过以下试验证明:
(a)膜剂的崩解:例如在体外以及在临床试验中在患者口中测量膜剂的崩解时间。
(b)膜剂的粘膜粘附性:例如用抗张强度测定仪测量膜剂的粘膜粘附性:在猪离体粘膜上对膜剂应用人工唾液,测量抗张强度(=最大分离力,单位mN)直到膜剂从粘膜上被撕下为止。例如,实施例1中的膜剂显示出838±119mN的高的粘膜粘附性,其与作为对照膜剂(与实施例1的膜剂相同但不合碱性物质碳酸钠)具有相同大小的粘膜粘附性。因此,令人吃惊的是实施例1中的膜剂中另外的碳酸钠的存在并没有降低其粘膜粘附性。
(c)稳定性试验:例如在严格控制的条件(温度/湿度)下在3个月或1年的研究中证明了膜剂的化学和物理稳定性。
可用本来已知的方法、例如以下实施例中所述的方法来制备本发明的口服可崩解膜剂。
以下实施例对本发明进行了举例说明。
实施例1:含有碳酸钠和交联羧甲基纤维素的口服可崩解膜剂(用于在口腔中调节pH)[=含有碳酸钠和烟碱酒石酸氢盐的双层口服可崩解膜剂的“层1”]
成分 量(mg)
羟丙基甲基纤维素(“HPMC”) 30.00
交联羧甲基纤维素钠 6.00
甘油 3.00
黄原胶 1.00
碳酸钠 8.00
薄荷醇 1.50
乙酰舒泛K 0.50
薄荷矫味剂 1.00
总干重 51.00
水 220.00
96%乙醇 140.00
总湿重 411.00
方法:将碳酸钠、乙酰舒泛K和薄荷醇溶解于水中。然后加入甘油和乙醇(碳酸钠沉淀)。在剧烈搅拌下缓慢地加入HPMC、交联羧甲基纤维素钠和黄原胶。保持缓慢搅拌,直到粘稠的混合物均匀为止。在一个平板上将该粘稠的混合物铺展成厚度均匀的一层并在烘箱中干燥(=“层1”)。
为了得到用于在口腔中调节pH的最终的口服可崩解膜剂,所述“层1”被进一步切割成例如2cm×3cm的长方形,然后将其独立包装在小袋中。
实施例2:含有3.067mg烟碱酒石酸氢盐(=1mg烟碱)、碳酸钠和交联羧甲基纤维素钠的双层口服可崩解膜剂
(A)含有烟碱酒石酸氢盐(具有交联羧甲基纤维素)的膜层的制备
成分 量(mg)
羟丙基甲基纤维素(“HPMC”) 30.00
交联羧甲基纤维素钠 6.00
甘油 3.00
黄原胶 1.00
烟碱酒石酸氢盐(=1mg烟碱) 3.07
薄荷醇 1.50
乙酰舒泛K 0.50
薄荷矫味剂 1.00
总干重 46.07
水 220.00
96%乙醇 140.00
总湿重 406.07
方法:将烟碱酒石酸氢盐、乙酰舒泛K和薄荷醇溶解于水-乙醇混合物中。然后加入甘油和液体薄荷矫味剂。在剧烈搅拌下缓慢地加入HPMC、交联羧甲基纤维素钠和黄原胶。保持缓慢搅拌,直到粘稠的混合物均匀为止。在一个平板上将该粘稠的混合物铺展成厚度均匀的一层并在烘箱中干燥。
(A1)含有烟碱酒石酸氢盐(不具有交联羧甲基纤维素)的膜层的制备:
成分 量(mg)
羟丙基甲基纤维素(“HPMC”) 30.00
甘油 4.00
黄原胶 3.00
烟碱酒石酸氢盐(=1mg烟碱) 3.07
薄荷醇 1.50
乙酰舒泛K 0.50
薄荷矫味剂 1.00
总干重 43.07
水 240.00
96%乙醇 250.00
总湿重 533.07
方法:将烟碱酒石酸氢盐、乙酰舒泛K和薄荷醇溶解于水-乙醇混合物中。然后加入甘油和液体薄荷矫味剂。在剧烈搅拌下缓慢地加入HPMC和黄原胶。保持缓慢搅拌,直到粘稠的混合物均匀为止。在一个平板上将该粘稠的混合物铺展成厚度均匀的一层并在烘箱中干燥。
(B)“层1”(参见实施例1)分别与层(A)或(A1)的结合:两个层通过以下方法结合:首先用乙醇喷雾对“层1”进行喷雾,然后对靠在“层1”上的层(A)[或(A1)]施以弱压力。将所得的双层膜干燥并切割成规定大小的双层口服可崩解膜剂(例如2cm×3cm的长方形),然后将其独立包装在小袋中。
实施例3:含有碳酸钠和玉米淀粉的口服可崩解膜剂(用于在口腔中调节pH)
成分 量(mg)
HPMC 25.00
玉米淀粉 15.00
甘油 3.00
黄原胶 1.00
碳酸钠 8.00
薄荷醇 1.50
乙酰舒泛K 0.50
薄荷矫味剂 1.00
总干重 55.00
水 200.00
96%乙醇 120.00
总湿重 375.00
方法:将碳酸钠、乙酰舒泛K和薄荷醇溶解于水中。然后加入甘油、液体薄荷矫味剂和乙醇(碳酸钠沉淀)。在剧烈搅拌下缓慢地加入HPMC、玉米淀粉和黄原胶。保持缓慢搅拌,直到粘稠的混合物均匀为止。在一个平板上将该粘稠的混合物铺展成厚度均匀的一层并在烘箱中干燥。最后,将所述的层切割成例如2cm×3cm的长方形,然后将其独立包装在小袋中。
Claims (19)
1.一种口服可崩解膜剂,其包含一个层,该层包含:
(a)成膜剂,
(b)选自由交联羧甲基纤维素钠、玉米淀粉、或其混合物组成的组的聚合物;和
(c)碱性物质。
2.根据权利要求1所述的口服可崩解膜剂,其还包含
(d)药学活性物质。
3.根据权利要求2所述的口服可崩解膜剂,其中所述的药学活性物质(d)易于与所述的碱性物质(c)发生化学反应,并且因此在所述的口服可崩解膜剂内与后者是分开的,以避免口服应用前任何过早的化学反应。
4.根据权利要求1-3中任意一项所述的口服可崩解膜剂,其中所述的成膜剂(a)选自由纤维素、纤维素醚衍生物、聚环氧烷、聚亚烷基二醇、聚亚烷基二醇共聚物、丙烯酸聚合物、丙烯酸共聚物、甲基丙烯酸聚合物、甲基丙烯酸共聚物、聚丙烯酰胺、支链淀粉、聚乙烯吡咯烷酮、聚乙烯醇、聚乙烯醇共聚物、羧乙烯聚合物、改性淀粉、直链淀粉、高直链淀粉、羟丙基化高直链淀粉、糊精、果胶、壳多糖、脱乙酰壳多糖、果聚糖、爱生兰、胶原、明胶、玉米醇蛋白、谷蛋白、大豆蛋白分离物、乳清蛋白分离物、酪蛋白、合成的或天然存在的树胶、角叉菜胶、海藻酸、海藻酸的盐、和其任何混合物组成的组。
5.根据权利要求1-4中任意一项所述的口服可崩解膜剂,其中所述的聚合物(b)是交联羧甲基纤维素钠。
6.根据权利要求1-5中任意一项所述的口服可崩解膜剂,其中所述的碱性物质(c)选自由碳酸钠、碳酸钾、碳酸氢钠、碳酸氢钾、氢氧化钠、氢氧化钾、或其任何混合物组成的组。
7.根据权利要求2-6中任意一项所述的口服可崩解膜剂,其中所述的药学活性物质(d)是烟碱活性剂。
8.根据权利要求1-7中任意一项所述的口服可崩解膜剂,其包含以下物质作为成膜剂(a):
(a1)水溶性成膜聚合物,和
(a2)0.1-20%重量的水胶体/生物聚合物胶。
9.根据权利要求8所述的口服可崩解膜剂,其包含0.3至5%重量的水胶体/生物聚合物胶(a2)。
10.根据权利要求1-9中任意一项所述的口服可崩解膜剂,其粘附于口腔粘膜上。
11.根据权利要求1-10中任意一项所述的口服可崩解膜剂,其在使用者的口中于1至10分钟内完全崩解。
12.根据权利要求1-11中任意一项所述的口服可崩解膜剂,其具有5至250微米的厚度。
13.根据权利要求8-12中任意一项所述的口服可崩解膜剂,其中所述的药学活性物质(a)是烟碱活性剂。
14.根据权利要求13所述的口服可崩解膜剂,其中所述的烟碱活性剂是烟碱盐。
15.根据权利要求14所述的口服可崩解膜剂,其中所述的烟碱盐是烟碱酒石酸氢盐。
16.根据权利要求8-15中任意一项所述的口服可崩解膜剂,其中水溶性成膜聚合物(a1)选自由纤维素、纤维素醚衍生物、聚亚烷基二醇共聚物、聚乙烯醇、聚乙烯醇共聚物、和其任何混合物组成的组。
17.根据权利要求8-15中任意一项所述的口服可崩解膜剂,其中所述的水溶性成膜聚合物(a1)是羟丙基甲基纤维素。
18.根据权利要求8-17中任意一项所述的口服可崩解膜剂,其中所述的水胶体/生物聚合物胶(a2)选自由合成的或天然存在的树胶、角叉菜胶、海藻酸、海藻酸的盐、和其混合物组成的组。
19.根据权利要求8-17中任意一项所述的口服可崩解膜剂,其中所述的水胶体/生物聚合物胶(a2)是黄原胶。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89341907P | 2007-03-07 | 2007-03-07 | |
US60/893,419 | 2007-03-07 | ||
PCT/US2008/002985 WO2008112124A2 (en) | 2007-03-07 | 2008-03-06 | Orally administrable films |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101621990A true CN101621990A (zh) | 2010-01-06 |
CN101621990B CN101621990B (zh) | 2012-11-21 |
Family
ID=39471953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008800062354A Expired - Fee Related CN101621990B (zh) | 2007-03-07 | 2008-03-06 | 可口服施用的膜剂 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8663659B2 (zh) |
EP (1) | EP2134321A2 (zh) |
JP (2) | JP5784878B2 (zh) |
CN (1) | CN101621990B (zh) |
CA (1) | CA2678876C (zh) |
WO (1) | WO2008112124A2 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102858327A (zh) * | 2010-04-27 | 2013-01-02 | 诺瓦提斯公司 | 口腔剂型 |
CN104203241A (zh) * | 2012-02-10 | 2014-12-10 | 尼科诺沃美国股份有限公司 | 多层含有烟碱的药物组合物 |
CN111372568A (zh) * | 2017-11-21 | 2020-07-03 | Lts勒曼治疗系统股份公司 | 水溶性聚合物粘合层 |
CN112075445A (zh) * | 2020-09-15 | 2020-12-15 | 湖北工程学院 | 一种交联羧甲基纤维素钠悬浮种衣剂及其制备方法 |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100508976C (zh) | 2003-07-24 | 2009-07-08 | 史密丝克莱恩比彻姆公司 | 口腔溶解薄膜 |
BRPI0709382A2 (pt) * | 2006-03-16 | 2011-07-12 | Novartis Ag | forma de dosagem sólida contendo um agente ativo de sabor mascarado |
JP5177447B2 (ja) | 2007-06-07 | 2013-04-03 | 佐藤製薬株式会社 | 速溶性及び可撓性を有するフィルム製剤 |
EP2674150A1 (de) * | 2009-01-28 | 2013-12-18 | Labtec GmbH | Pharmazeutische Zubereitung mit verbesserter Stabilität des Wirkstoffs |
CA2759985A1 (en) | 2009-05-12 | 2010-11-18 | Bpsi Holdings, Llc | Enhanced moisture barrier immediate release film coating systems and substrates coated therewith |
US9155321B2 (en) | 2010-08-11 | 2015-10-13 | R.J. Reynolds Tobacco Company | Meltable smokeless tobacco composition |
US11116237B2 (en) | 2010-08-11 | 2021-09-14 | R.J. Reynolds Tobacco Company | Meltable smokeless tobacco composition |
WO2012053006A2 (en) * | 2010-10-18 | 2012-04-26 | Panacea Biotec Ltd | Improved oral fast dissolving films comprising combination of polymers and method of preparation thereof |
US9775376B2 (en) | 2010-12-01 | 2017-10-03 | R.J. Reynolds Tobacco Company | Smokeless tobacco pastille and moulding process for forming smokeless tobacco products |
JP5763994B2 (ja) | 2011-07-13 | 2015-08-12 | 日東電工株式会社 | ゼリー状製剤及びゼリー状製剤の製造方法 |
US9474303B2 (en) | 2011-09-22 | 2016-10-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
US9629392B2 (en) | 2011-09-22 | 2017-04-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9084439B2 (en) | 2011-09-22 | 2015-07-21 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9044035B2 (en) | 2012-04-17 | 2015-06-02 | R.J. Reynolds Tobacco Company | Remelted ingestible products |
AU2012396806B2 (en) * | 2012-12-14 | 2015-11-05 | Colgate-Palmolive Company | Abradable films for use in oral care |
US10357054B2 (en) | 2013-10-16 | 2019-07-23 | R.J. Reynolds Tobacco Company | Smokeless tobacco pastille |
KR101467853B1 (ko) * | 2014-04-01 | 2014-12-03 | 창성소프트젤 주식회사 | 탄성 및 접착성이 우수하고 얇은 피막으로 생산성과 붕해도가 향상되는 식물성 연질캡슐 및 그의 조성물과 그 제조방법 |
CN106822007B (zh) | 2015-09-11 | 2021-12-31 | 西姆莱斯股份公司 | 口服制剂 |
US11648212B2 (en) * | 2016-02-03 | 2023-05-16 | Intelgenx Corp. | Loxapine film oral dosage form |
EP3478274A4 (en) * | 2016-06-30 | 2020-03-04 | TAHO Pharmaceuticals Ltd. | FAST-EFFECTING FILM FOR THE ADMINISTRATION OF A LOCAL ANESTHESIA IN THE MOUTH |
IL247161A0 (en) * | 2016-08-08 | 2016-12-29 | Rubin Yoram | Fast-dissolving adhesive films for the treatment of oral conditions |
US10906950B2 (en) | 2016-08-19 | 2021-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Alkaline pH-modified edible casein-based films and coatings, and method for the making thereof |
UA128427C2 (uk) * | 2018-04-06 | 2024-07-10 | Філіп Морріс Продактс С.А. | Нікотиновий гель |
US11911492B2 (en) | 2018-05-14 | 2024-02-27 | The Procter & Gamble Company | Oral care compositions comprising metal ions |
WO2019222126A1 (en) * | 2018-05-14 | 2019-11-21 | The Procter & Gamble Company | Oral care compositions comprising metal ions |
CN109513035B (zh) * | 2018-12-13 | 2021-10-08 | 广州润虹医药科技股份有限公司 | 一种多功能水胶体敷料及其制备方法 |
DE102019135432A1 (de) * | 2019-12-20 | 2021-06-24 | Lts Lohmann Therapie-Systeme Ag | Lösliche Rückschicht für OTF |
WO2021228358A1 (en) | 2020-05-11 | 2021-11-18 | Symrise Ag | A solid mucoadhesive composition |
EP4119123A1 (en) * | 2021-07-14 | 2023-01-18 | G.L. Pharma GmbH | Orally disintegrating film composition comprising buprenorphine |
CN114099475B (zh) * | 2021-11-08 | 2023-05-09 | 华南农业大学 | 一步法制备界面多孔活性控释膜及其应用 |
WO2024016113A1 (en) * | 2022-07-18 | 2024-01-25 | Yimin Sun | Sublingual mucus adhesion drug delivery |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2703795A (en) | 1994-06-23 | 1996-01-19 | Procter & Gamble Company, The | Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine |
DE19646392A1 (de) * | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
US6596298B2 (en) * | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
DE10018834A1 (de) | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
EP1389910A4 (en) | 2001-04-20 | 2005-11-02 | Lavipharm Lab Inc | INTRABUCAL DISTRIBUTION OF NICOTINE INTENDED TO STOP SMOKING |
JP5089840B2 (ja) | 2001-09-25 | 2012-12-05 | 救急薬品工業株式会社 | ニコチン含有フィルム製剤 |
JP2005522991A (ja) * | 2001-11-16 | 2005-08-04 | ジボダン エス エー | 可食性フィルム |
DE10207394B4 (de) * | 2002-02-21 | 2007-03-29 | Lts Lohmann Therapie-Systeme Ag | Geschmacksmaskierte oblatenförmige Arzneizubereitung |
US20030194420A1 (en) | 2002-04-11 | 2003-10-16 | Richard Holl | Process for loading a drug delivery device |
DE10256775A1 (de) * | 2002-12-05 | 2004-06-24 | Lts Lohmann Therapie-Systeme Ag | Filmförmige Zubereitungen zur transmucosalen Verabreichung von Nicotin, sowie Verfahren zu deren Herstellung |
CN100508976C (zh) * | 2003-07-24 | 2009-07-08 | 史密丝克莱恩比彻姆公司 | 口腔溶解薄膜 |
US7817567B2 (en) | 2003-07-28 | 2010-10-19 | Jds Uniphase Corporation | Troubleshooting a specific voice over internet protocol (VOIP) telephone call transmitted over a communications network |
MX2007004495A (es) * | 2004-10-15 | 2007-05-10 | Pfizer Prod Inc | Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina. |
WO2006063189A2 (en) * | 2004-12-10 | 2006-06-15 | Novartis Ag | Multi-layered chewing gum tablet with quick disintegration layer |
-
2008
- 2008-03-06 JP JP2009552732A patent/JP5784878B2/ja not_active Expired - Fee Related
- 2008-03-06 CA CA2678876A patent/CA2678876C/en not_active Expired - Fee Related
- 2008-03-06 CN CN2008800062354A patent/CN101621990B/zh not_active Expired - Fee Related
- 2008-03-06 US US12/529,659 patent/US8663659B2/en not_active Expired - Fee Related
- 2008-03-06 WO PCT/US2008/002985 patent/WO2008112124A2/en active Application Filing
- 2008-03-06 EP EP20080726504 patent/EP2134321A2/en not_active Withdrawn
-
2013
- 2013-12-05 JP JP2013251869A patent/JP2014074043A/ja active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102858327A (zh) * | 2010-04-27 | 2013-01-02 | 诺瓦提斯公司 | 口腔剂型 |
CN104203241A (zh) * | 2012-02-10 | 2014-12-10 | 尼科诺沃美国股份有限公司 | 多层含有烟碱的药物组合物 |
CN111372568A (zh) * | 2017-11-21 | 2020-07-03 | Lts勒曼治疗系统股份公司 | 水溶性聚合物粘合层 |
CN111372568B (zh) * | 2017-11-21 | 2023-11-07 | Lts勒曼治疗系统股份公司 | 水溶性聚合物粘合层 |
CN112075445A (zh) * | 2020-09-15 | 2020-12-15 | 湖北工程学院 | 一种交联羧甲基纤维素钠悬浮种衣剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2014074043A (ja) | 2014-04-24 |
WO2008112124A3 (en) | 2009-04-09 |
EP2134321A2 (en) | 2009-12-23 |
US8663659B2 (en) | 2014-03-04 |
CA2678876C (en) | 2015-11-24 |
WO2008112124A2 (en) | 2008-09-18 |
JP2010520287A (ja) | 2010-06-10 |
US20100063110A1 (en) | 2010-03-11 |
CA2678876A1 (en) | 2008-09-18 |
JP5784878B2 (ja) | 2015-09-24 |
CN101621990B (zh) | 2012-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101621990B (zh) | 可口服施用的膜剂 | |
US8840935B2 (en) | Orally administrable films and preparation thereof | |
CN100389755C (zh) | 粘膜传递的组合物及方法 | |
CN101043880B (zh) | 包含双氯芬酸的药物组合物 | |
CN100508976C (zh) | 口腔溶解薄膜 | |
US20070042023A1 (en) | Dissolvable film | |
Mahajan et al. | Mucoadhesive drug delivery system: a review | |
WO2005082048A2 (en) | Dissolvable film and method of manufacture | |
MX2008005874A (es) | Peliculas y capsulas elaboradas de materiales de carboximetilcelulosa modificada y metodos para elaborarlas. | |
WO2003026654A1 (fr) | Preparation pour film contenant de la nicotine | |
CA2674116A1 (en) | Solid film, rapidly dissolvable in liquids | |
TW200307566A (en) | Active substance-containing film like preparations having improved chemical stability, and processes for their preparation | |
CN101449631A (zh) | 由改良的羧甲基纤维素材料制成的薄膜和胶囊及其制备方法 | |
TW200502008A (en) | Patches for mucosa of oral cavity containing fentanyl | |
CA2795304A1 (en) | Oral dosage forms | |
TW200848094A (en) | Fast disintegration monolayer film for buccal administration of active substances | |
TWI429454B (zh) | 口腔用組成物 | |
TWI424854B (zh) | 口腔用組成物(二) | |
JP5322004B2 (ja) | 嚥下補助剤 | |
WO2023250297A1 (en) | Film forming delayed/enteric formulations for hard shell capsules, films and coatings | |
US20150320676A1 (en) | Topical drug for treating aphthae |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER NAME: NOVARTIS AG |
|
CP01 | Change in the name or title of a patent holder |
Address after: Basel Patentee after: Novartis Ag Address before: Basel Patentee before: Novartis AG |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121121 Termination date: 20190306 |